ICMR's deadline for Covid-19 vaccine launch an 'unscientific gaffe': Sibal

Bharat Biotech had recently received a nod for a clinical trial of its vaccine - Covaxin

Kapil Sibal
A total of 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine
ANI
1 min read Last Updated : Jul 06 2020 | 12:34 PM IST

Congress leader Kapil Sibal on Sunday described as "unscientific gaffe" the Indian Council of Medical Research's (ICMR) claim to launch a vaccine for Covid-19 by August 15 

Taking to Twitter, Sibal wrote, "Unscientific gaffes: ICMR claim: COVID 19 vaccine by August 15 Mahabharat over in 18 days; wait 21 days and this war will be won Chants of: Carona go, Caron go...Cow dung cures cancer Ganesh's head: miracle of surgery Such mindsets can never provide solutions."

The comments of the Congress leader came after ICMR DG Balram Bhargava's letter to Bharat Biotech and principal investigators of medical colleges to complete the trial procedure of indigenous COVID-19 vaccine in a fast track method so that results of a clinical trial can be launched by August 15.

Bharat Biotech had recently received a nod for a clinical trial of its vaccine - Covaxin. A total of 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered the topmost priority projects which are being monitored by the government.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBharat BiotechKapil Sibal

Next Story